Ioannis Zerdes1, Maria Tolia2, Nikolaos Tsoukalas3, Michail Mitsis4, Dimitrios Kardamakis5, Kyriaki Pistevou-Gombaki6, Perikles Tsekeris7, George Kyrgias2. 1. 1 Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece. 2. 2 Department of Radiotherapy, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece. 3. 3 Department of Oncology, Veterans Hospital (NIMTS), Athens, Greece. 4. 4 Surgery Clinic, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece. 5. 5 Department of Radiation Oncology, University of Patras Medical School, Patras, Greece. 6. 6 Radiation Oncology Clinic, University General Hospital of Thessaloniki AHEPA, Thessaloniki, Greece. 7. 7 Department of Radiotherapy, University Hospital of Ioannina, Ioannina, Greece.
Abstract
INTRODUCTION: : Renal cell carcinoma represents a neoplasm with usually aggressive behavior. Due to its nature, it is often diagnosed in an advanced stage or when metastatic dissemination has been occurred. The aim of this review is to provide an overview of the current management of metastatic renal cell carcinoma and briefly discuss the potential new therapeutic strategies for this disease. METHODS: : Review of the literature was performed in PubMed/MEDLINE, Cochrane, and EMBASE and we included English articles up to February 2018. RESULTS: : Over the past years, many efforts have been made in the context of confronting metastatic disease and led to the introduction of targeted therapies. More available agent options, including various tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors, can be served nowadays as the first-, second-, and third-line therapy in the metastatic setting of the disease providing better outcomes. DISCUSSION:: Moreover, regarding the recent advances in the field of cancer immunotherapy, the landscape of metastatic renal cell carcinoma management is being shaped toward novel immunotherapeutic interventions alone or in combination with other types of therapy.
INTRODUCTION: : Renal cell carcinoma represents a neoplasm with usually aggressive behavior. Due to its nature, it is often diagnosed in an advanced stage or when metastatic dissemination has been occurred. The aim of this review is to provide an overview of the current management of metastatic renal cell carcinoma and briefly discuss the potential new therapeutic strategies for this disease. METHODS: : Review of the literature was performed in PubMed/MEDLINE, Cochrane, and EMBASE and we included English articles up to February 2018. RESULTS: : Over the past years, many efforts have been made in the context of confronting metastatic disease and led to the introduction of targeted therapies. More available agent options, including various tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors, can be served nowadays as the first-, second-, and third-line therapy in the metastatic setting of the disease providing better outcomes. DISCUSSION:: Moreover, regarding the recent advances in the field of cancer immunotherapy, the landscape of metastatic renal cell carcinoma management is being shaped toward novel immunotherapeutic interventions alone or in combination with other types of therapy.
Authors: Dmitry S Mikhaylenko; Alexey V Klimov; Vsevolod B Matveev; Svetlana I Samoylova; Vladimir V Strelnikov; Dmitry V Zaletaev; Ludmila N Lubchenko; Boris Y Alekseev; Marina V Nemtsova Journal: Front Oncol Date: 2020-01-21 Impact factor: 6.244